Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito) commemorated the opening of its newly constructed parenteral facility in Research Triangle Park (RTP), North Carolina. The new site will be utilized for the commercial production and formulation research and development of intravenous treatments.
The 65-K sqft facility will serve as Eisai’s global commercial manufacturing and drug development site for intravenous drug products in support of the company’s global clinical development programs, including those for oncology. Eisai invested approximately $100-M in the new facility, which encompasses aseptic processing suites, laboratories and other support functions. The new operation is designed to handle and process highly potent compounds utilizing state-of-the-art isolator containment technology.
The new site will complement Eisai’s existing 190-K sqft operation, which is utilized for the commercial manufacturing of oral solid dose products as well as the formulation and development of compounds for use in clinical trials. The exceptional growth of the company has led Eisai to expand its presence in North Carolina for the third time since 2001. In addition, a separate $22-M central utilities building was opened in 2008 to supply power, steam, chilled water and compressed air to the existing operation, new parenteral facility and for future expansions.
In 1997 Eisai Inc. opened an 85-K sqft, state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, North Carolina. Since its opening, the facility has more than doubled in size with the completion of a second expansion in 2003.